Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
Guidelines for national programmes and other stakeholders
Annexes for webposting and CD-Rom distribution with the policy guidelines
Networking for Policy Change: TB/HIV Participant’s Guide
WHO/HTM/TB/2007.384b
“TB is too often a death sentence for people with AIDS. It does not have to be this
way.”
-Nelson Mandela, International conference on HIV and AIDS, Bangkok, Thailand, July 2004.
54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
10–11 May 2016, Catania, Italy
First WHO Global Ministerial Conference
Ending TB in the Sustainable Development Era: A Multisectoral Response
Moscow, Russian Federation, 16-17 November 2017
The publication describes techniques of narrative therapy discussed in a workshop series for Jiyan Foundation staff members by David Denborough (Dulwich Center Foundation). The publication also includes contributions from local staff reporting on self-assertion and survival strategies of Kurdish fam...ilies
more
Further Analysis of the 2000, 2005, and 2011 Demographic and Health Surveys. DHS Further Analysis Reports No. 83
This is the Technical Annex for the BRACED report: Measuring changes in household resilience as a result of BRACED activities in Myanmar.
The study analyses the current situation of children with disabilities in relation to realizing their rights and accessing basic services, as well as their life experiences in their communities. It also focuses on identifying the barriers created by society that prevent children with disabilities fr...om enjoying their human rights. This includes identifying negative attitudes; environmental and communication barriers; gaps in policies or their effective implementation.
The report reveals that children with disabilities in Myanmar are less likely to access services in health or education; rarely have their voices heard in society; and face daily discrimination as objects of pity. It also highlights how inadequate policies and legislation contribute to the challenges these children face.
The information available in this publication should be useful for policy makers, development partners and Disabled Persons Organisations to promote the realization of the rights of all children with disabilities.
more
A Review of Evidence from Africa
Accessed: 21.08.2019
BMJ VOLUME 322 24 FEBRUARY 2001 bmj.com
Child Survival Working Group
Accessed: 26.10.2019
Journal of Social Aspects of HIV/AIDS VOL. 13 NO. 1 2016
To link to this article: https://doi.org/10.1080/17290376.2016.1226942
The recommendation in this document thus supersedes the previous WHO recommendation for the prevention of PPH as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage.